Serotype replacement in Streptococcus pneumoniae after conjugate vaccine introduction: Impact, doubts and perspective for new vaccines

Reviews and Research in Medical Microbiology

Volumn 21, Issue 3, 2010, Pages 56-64

  Filippo, Ansaldi ^a,b   Daniela, De Florentiis ^b   Paola, Canepa ^a   Paolo, Durando ^a,b   Matteo, Bassetti ^b   Giancarlo, Icardi ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

capsular switching; invasive pneumococcal disease; pneumococcal vaccination; replacement

Indexed keywords

AZITHROMYCIN; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL GENETICS; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CLONAL VARIATION; DRUG EFFECT; DRUG EFFICACY; EUROPE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INCIDENCE; INFECTION SENSITIVITY; INVASIVE PNEUMOCOCCAL DISEASE; MENINGITIS; NONHUMAN; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SEROTYPE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

EID: 77954659281     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MRM.0b013e32833a345f     Document Type: Review

References (50)

1. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357:1008-1011.
2. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-1746.
3. Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, et al. Effectiveness of a 2R1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26:3277-3281.
4. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009; 360:244-256.
5. Black S, Shinefield H, Baxter R, Austrian R, Elvin L, Hansen J, et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine 2006; 24 (Suppl 2):79-80.
6. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294:2043-2051.
7. Centers for Disease Control and Prevention (CDC). Direct and indirect effect of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. Mmwr Morb Mortal Wkly Rep 2005; 54:893-897.
8. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-212.
9. Cohen R, Levy C, de La Rocque F, Gelbert N, Wollner A, Fritzell B, et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006; 25:1001-1007.
10. Cohen R, Levy C, Bonnet E, Grondin S, Desvignes V, Lecuyer A, et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2009. [Epub ahead of print]
11. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, Hennessy TW. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis 2006; 193:1487-1494.
12. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348:271-272.
13. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002; 185:927-936.
14. Beal B, McEllistrem MC, Gertz jr RE, Wedel S, Boxrud DJ, Gonzalez AL, et al. Pre and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001 and 2002. J Clin Microbiol 2006; 44:999-1017.
15. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, Active bacterial core surveillance team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005; 192:1988-1995.
16. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007; 3:e168.
17. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, Lee HJ. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis 2008; 14:275-281.
18. Hanquet G, Kissling E, Tarrago D, Fenoll A, Varon E, Robert G, et al. Dynamic changes of three nonvaccine pneumococcal serotypes in Spain, France, Belgium and England & Wales, 1996-2006 [abstract S01-04]. In: Abstracts of the Sixth International Symposium on Pneumococci and Pneumococcal Diseases (Reykjavik). 2008. p. 38.
19. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009; 199:776-785.
20. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption?. J Chemother 1999; 11:35-43.
21. Dagan R, Barkai G, Givon-Lavi N, Sharf AZ, Vardy D, Cohen T. Seasonality of antibiotic-resistant Streptococcus pneumoniae that causes acute otitis media: a clue for an antibiotic-restriction policy?. J Infect Dis 2008; 197:1094-1102.
22. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991-1999. Ann Intern Med 2003; 138:525-533.
23. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.
24. Huang SS, Finkelstein JA, Rifas-Shiman SL, Kleinman K, Platt R. Community-level predictors of pneumococcal carriage and resistance in young children. Am J Epidemiol 2004; 159:645-654.
25. Hansman D, Morris S, Gregory M, Mc-Donald B. Pneumococcal carriage amongst Australian aborigines in Alice Springs, Northern Territory. J Hyg (Lond) 1985; 95:677-684.
26. Singleton RJ, Hennessy TW, Bulkow LR. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297:1784-1792.
27. Ihekweazu CA, Dance DA, Pebody R. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol Infect 2008; 136:1096-1102.
28. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002; 35:547-555.
29. Flamaing J, Verhaegen J, Vandeven J, Verbiest N, Peetermans WE. Pneumococcal bacteraemia in Belgium (1994-2004): the preconjugate vaccine era. J Antimicrob Chemother 2008; 61:143-149.
30. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006; 295:1668-1674.
31. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1569-1576.
32. Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008; 47:476-484.
33. Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007; 26:771-777.
34. Bingen E, Levy C, Varon E, de La Rocque F, Boucherat M, d'Athis P, et al., Bacterial Meningitis Study Group. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis 2008; 27:191-199.
35. Aristegui J, Bernaola E, Pocheville I, García C, Arranz L, Durán G, Pérez L, et al. Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 2007; 26:303-310.
36. Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009; 15:1013-1019.
37. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46:174-182.
38. Calbo E, DÍaz A, Cañadell E, Fábrega J, Uriz S, Xercavins M, et al., Spanish Pneumococcal Infection Study Network. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006; 12:867-872.
39. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M, Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with nonuniversal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008; 14:835-843.
40. Clarke SC, Jefferies JM, Smith AJ, McMenamin J, Mitchell TJ, Edwards GF. Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. J Clin Microbiol 2006; 44:1224-1228.
41. Ansaldi F, Sticchi L, Durando P, Carloni R, Oreste P, Vercelli M, et al. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J Int Med Res 2008; 36:1255-1260.
42. Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, et al., Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine 2009; 27 (25-26):3459-3462.
43. Fenoll A, Granizo JJ, Aguilar L, Giménez MJ, Aragoneses-Fenoll L, Hanquet G, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47:1012-1020.
44. Tarallo L, Tancredi F, Schito G, Marchese A, Bella A, Italian Pneumonet Group (Società Italiana Pediatria and Associazione Italiana Studio Antimicrobici e Resistenze). Active surveillance of Streptococcus pneumoniae bacteremia in Italian children. Vaccine 2006; 24:6938-6943.
45. Gherardi G, Fallico L, Del Grosso M, Bonanni F, D'Ambrosio F, Manganelli R, et al. Antibiotic-resistant invasive pneumococcal clones in Italy. J Clin Microbiol 2007; 45:306-312.
46. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14:e197-e209.
47. van den Linden M, Reinert R. Surveillance of IPD in children in Germany 2004-2008, before and after the introduction of the national immunization programme for PCV7. In: Abstracts of the Sixth International Symposium on Pneumococci and Pneumococcal Diseases (Reykjavik). 2008; pp. 27-28.
48. van den Linden, Reinert R. Effects of the national immunization programme for PCV7 on IPD in Germany. 6th International symposium on Pneumococci and Pneumococcal diseases; 2008.
49. Benito-Fernández J, Raso SM, Pocheville-Gurutzeta I, SánchezEtxaniz J, Azcunaga-Santibañez B, Capapé-Zache S. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. Pediatr Infect Dis J 2007; 26:667-671.
50. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 2009; 28:277-282.